RayzeBio Appoints Christy Oliger to its Board of Directors

SAN DIEGO--(BUSINESS WIRE)--RayzeBio, Inc., a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, appointed Christy Oliger to its board of directors. Ms. Oliger brings over 30 years of experience in the biopharmaceutical industry as a board member and executive, serving in various commercial and portfolio management roles at Genentech, Inc., Roche Holding AG and Schering-Plough Corporation.

“I am very excited about the impact RayzeBio can have on cancer patients and the broader targeted radiopharmaceutical field. I look forward to working with RayzeBio’s accomplished management team on the company’s next phase of growth,” said Ms. Oliger.

“I am delighted to welcome Christy to our board of directors. Christy has a wealth of experience in commercializing innovative products. She will be an invaluable resource to RayzeBio as we continue to advance our lead clinical program in a Phase 3 clinical trial,” said Ken Song, M.D., President and CEO of RayzeBio.

During her over 30-year career, Ms. Oliger served in various commercial roles at Genentech, Inc. and Roche Holding AG from January 2000 until her retirement in July 2020, and at Schering-Plough Corporation from September 1992 until December 1999. Most recently, Ms. Oliger served as Senior Vice President, Oncology Business Unit Head, at Genentech, Inc. During her tenure at Genentech, Inc., Ms. Oliger held senior leadership roles across a variety of therapeutic areas, including oncology, neurology, rare diseases, respiratory, dermatology and immunology in hospital and specialty settings. She currently serves as a member of the board of directors of Reata Pharmaceuticals, Inc., Replimune Group Inc., Karyopharm Therapeutics Inc., and Lava Therapeutics, each of which is a publicly-traded pharmaceutical company. Previously, Ms. Oliger also served on the board of Sierra Oncology, Inc. which was acquired by GSK for $1.9 billion. Ms. Oliger received a B.A. in Economics from the University of California at Santa Barbara.

About RayzeBio

RayzeBio is a biotechnology company focused on improving outcomes for people with cancer by harnessing the power of targeted radioisotopes. With a focus on clinically validated solid tumor targets, RayzeBio is developing novel drug conjugates to deliver potent therapeutic radioisotopes such as Actinium-225, an alpha-emitter. For additional information, please visit www.rayzebio.com.